Georgetown University
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Metastatic Pancreatic Ductal Adenocarcinoma
BXCL701
Pembrolizumab
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 43 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
Actual Study Start Date : | August 16, 2023 |
Estimated Primary Completion Date : | November 2026 |
Estimated Study Completion Date : | November 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: BXCL701 plus Pembrolizumab |
Drug: BXCL701 Other: Pembrolizumab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Georgetown Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States, 20007